Windtree Therapeutics, Inc. (WINTW)
USD 0.0
(-61.11%)
USD 0.0
(-61.11%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -17.53 Million USD | 57.57% |
| 2022 | -41.33 Million USD | 46.52% |
| 2021 | -77.28 Million USD | -154.91% |
| 2020 | -30.31 Million USD | -21.79% |
| 2019 | -24.89 Million USD | -53.71% |
| 2018 | -16.19 Million USD | 28.18% |
| 2017 | -22.54 Million USD | 40.72% |
| 2016 | -38.03 Million USD | 4.51% |
| 2015 | -39.83 Million USD | 7.92% |
| 2014 | -43.25 Million USD | 2.81% |
| 2013 | -44.5 Million USD | -17.69% |
| 2012 | -37.81 Million USD | -54.29% |
| 2011 | -24.51 Million USD | 3.98% |
| 2010 | -25.52 Million USD | 12.57% |
| 2009 | -29.19 Million USD | 23.95% |
| 2008 | -38.39 Million USD | 3.89% |
| 2007 | -39.94 Million USD | 14.84% |
| 2006 | -46.9 Million USD | 20.89% |
| 2005 | -59.29 Million USD | -28.81% |
| 2004 | -46.03 Million USD | -88.39% |
| 2003 | -24.43 Million USD | -35.58% |
| 2002 | -18.02 Million USD | -50.67% |
| 2001 | -11.96 Million USD | -0.54% |
| 2000 | -11.89 Million USD | -132.75% |
| 1999 | -5.11 Million USD | 34.46% |
| 1998 | -7.8 Million USD | 15.22% |
| 1997 | -9.2 Million USD | -300.0% |
| 1996 | -2.3 Million USD | 4.17% |
| 1995 | -2.4 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -11.45 Million USD | -159.98% |
| 2024 Q1 | -4.4 Million USD | 11.17% |
| 2023 Q2 | -6.75 Million USD | -61.23% |
| 2023 Q4 | -4.95 Million USD | -5.74% |
| 2023 FY | -17.53 Million USD | 57.57% |
| 2023 Q3 | -4.69 Million USD | 30.59% |
| 2023 Q1 | -4.19 Million USD | 61.24% |
| 2022 FY | -41.33 Million USD | 46.52% |
| 2022 Q1 | -8.33 Million USD | 43.28% |
| 2022 Q2 | -17.53 Million USD | -110.46% |
| 2022 Q3 | -4.65 Million USD | 73.49% |
| 2022 Q4 | -10.81 Million USD | -132.52% |
| 2021 Q3 | -8.14 Million USD | 82.04% |
| 2021 Q2 | -45.36 Million USD | -399.64% |
| 2021 Q1 | -9.07 Million USD | -30.43% |
| 2021 FY | -77.28 Million USD | -154.91% |
| 2021 Q4 | -14.69 Million USD | -80.34% |
| 2020 Q4 | -6.96 Million USD | 20.03% |
| 2020 Q1 | -6.7 Million USD | -47.19% |
| 2020 Q2 | -7.94 Million USD | -18.57% |
| 2020 FY | -30.31 Million USD | -21.79% |
| 2020 Q3 | -8.7 Million USD | -9.52% |
| 2019 FY | -24.89 Million USD | -53.71% |
| 2019 Q4 | -4.55 Million USD | 36.64% |
| 2019 Q3 | -7.18 Million USD | -10.65% |
| 2019 Q2 | -6.49 Million USD | 2.43% |
| 2019 Q1 | -6.65 Million USD | -37.23% |
| 2018 Q3 | -3.46 Million USD | -14.23% |
| 2018 FY | -16.19 Million USD | 28.18% |
| 2018 Q1 | -4.84 Million USD | -38.36% |
| 2018 Q2 | -3.03 Million USD | 37.27% |
| 2018 Q4 | -4.85 Million USD | -39.88% |
| 2017 Q1 | -8.11 Million USD | -27.45% |
| 2017 Q2 | -6.14 Million USD | 24.35% |
| 2017 Q4 | -3.49 Million USD | 27.03% |
| 2017 Q3 | -4.79 Million USD | 21.92% |
| 2017 FY | -22.54 Million USD | 40.72% |
| 2016 FY | -38.03 Million USD | 4.51% |
| 2016 Q4 | -6.36 Million USD | 17.65% |
| 2016 Q1 | -13.94 Million USD | -42.54% |
| 2016 Q3 | -7.73 Million USD | 22.62% |
| 2016 Q2 | -9.99 Million USD | 28.32% |
| 2015 Q1 | -11.17 Million USD | 0.47% |
| 2015 Q3 | -8.44 Million USD | 19.11% |
| 2015 Q2 | -10.43 Million USD | 6.59% |
| 2015 Q4 | -9.78 Million USD | -15.85% |
| 2015 FY | -39.83 Million USD | 7.92% |
| 2014 Q4 | -11.22 Million USD | -8.71% |
| 2014 Q1 | -10.76 Million USD | -4.85% |
| 2014 Q3 | -10.32 Million USD | 5.62% |
| 2014 Q2 | -10.94 Million USD | -1.66% |
| 2014 FY | -43.25 Million USD | 2.81% |
| 2013 Q2 | -10.81 Million USD | 14.34% |
| 2013 Q4 | -10.26 Million USD | 5.07% |
| 2013 Q3 | -10.81 Million USD | -0.03% |
| 2013 Q1 | -12.62 Million USD | -1.57% |
| 2013 FY | -44.5 Million USD | -17.69% |
| 2012 Q3 | -9.99 Million USD | -13.41% |
| 2012 Q4 | -12.42 Million USD | -24.27% |
| 2012 Q2 | -8.81 Million USD | -33.98% |
| 2012 FY | -37.81 Million USD | -54.29% |
| 2012 Q1 | -6.58 Million USD | -11.47% |
| 2011 Q2 | -6.38 Million USD | -5.3% |
| 2011 Q4 | -5.9 Million USD | 4.33% |
| 2011 FY | -24.51 Million USD | 3.98% |
| 2011 Q3 | -6.17 Million USD | 3.29% |
| 2011 Q1 | -6.05 Million USD | -0.45% |
| 2010 FY | -25.52 Million USD | 12.57% |
| 2010 Q1 | -7.06 Million USD | -19.68% |
| 2010 Q2 | -6.22 Million USD | 11.85% |
| 2010 Q4 | -6.03 Million USD | 2.76% |
| 2010 Q3 | -6.2 Million USD | 0.4% |
| 2009 Q1 | -8.7 Million USD | -4.96% |
| 2009 Q3 | -6.94 Million USD | 9.12% |
| 2009 FY | -29.19 Million USD | 23.95% |
| 2009 Q2 | -7.64 Million USD | 12.17% |
| 2009 Q4 | -5.9 Million USD | 15.03% |
| 2008 FY | -38.39 Million USD | 3.89% |
| 2008 Q3 | -10.4 Million USD | -3.84% |
| 2008 Q4 | -8.29 Million USD | 20.27% |
| 2008 Q2 | -10.01 Million USD | -3.39% |
| 2008 Q1 | -9.68 Million USD | 20.47% |
| 2007 Q3 | -9.33 Million USD | 9.05% |
| 2007 Q2 | -10.25 Million USD | -25.48% |
| 2007 Q1 | -8.17 Million USD | -2.91% |
| 2007 FY | -39.94 Million USD | 14.84% |
| 2007 Q4 | -12.18 Million USD | -30.54% |
| 2006 Q3 | -7.92 Million USD | 46.22% |
| 2006 FY | -46.9 Million USD | 20.89% |
| 2006 Q4 | -7.94 Million USD | -0.23% |
| 2006 Q1 | -16.29 Million USD | 44.87% |
| 2006 Q2 | -14.74 Million USD | 9.54% |
| 2005 FY | -59.29 Million USD | -28.81% |
| 2005 Q2 | -9.93 Million USD | -6.5% |
| 2005 Q1 | -9.32 Million USD | 53.32% |
| 2005 Q3 | -10.47 Million USD | -5.42% |
| 2005 Q4 | -29.55 Million USD | -182.23% |
| 2004 Q2 | -8.85 Million USD | -0.02% |
| 2004 Q4 | -19.98 Million USD | -139.51% |
| 2004 Q3 | -8.34 Million USD | 5.72% |
| 2004 FY | -46.03 Million USD | -88.39% |
| 2004 Q1 | -8.84 Million USD | -2.17% |
| 2003 FY | -24.43 Million USD | -35.58% |
| 2003 Q3 | -6.27 Million USD | -28.41% |
| 2003 Q2 | -4.88 Million USD | -5.78% |
| 2003 Q1 | -4.61 Million USD | 12.98% |
| 2003 Q4 | -8.66 Million USD | -38.07% |
| 2002 Q2 | -4.47 Million USD | -27.89% |
| 2002 Q1 | -3.5 Million USD | 30.43% |
| 2002 Q3 | -4.74 Million USD | -5.9% |
| 2002 Q4 | -5.3 Million USD | -11.96% |
| 2002 FY | -18.02 Million USD | -50.67% |
| 2001 Q1 | -2.05 Million USD | 70.0% |
| 2001 Q4 | -5.03 Million USD | -104.76% |
| 2001 FY | -11.96 Million USD | -0.54% |
| 2001 Q3 | -2.45 Million USD | -4.38% |
| 2001 Q2 | -2.35 Million USD | -14.33% |
| 2000 Q4 | -6.86 Million USD | -311.94% |
| 2000 Q3 | -1.66 Million USD | 11.29% |
| 2000 Q2 | -1.87 Million USD | -27.93% |
| 2000 Q1 | -1.46 Million USD | -11.89% |
| 2000 FY | -11.89 Million USD | -132.75% |
| 1999 Q1 | -1.9 Million USD | 9.52% |
| 1999 Q4 | -1.31 Million USD | -87.43% |
| 1999 Q3 | -700 Thousand USD | 36.36% |
| 1999 FY | -5.11 Million USD | 34.46% |
| 1999 Q2 | -1.1 Million USD | 42.11% |
| 1998 Q4 | -2.1 Million USD | -75.0% |
| 1998 Q3 | -1.2 Million USD | 47.83% |
| 1998 Q2 | -2.3 Million USD | -4.55% |
| 1998 Q1 | -2.2 Million USD | 71.79% |
| 1998 FY | -7.8 Million USD | 15.22% |
| 1997 Q2 | -400 Thousand USD | 33.33% |
| 1997 Q1 | -600 Thousand USD | 14.29% |
| 1997 Q3 | -200 Thousand USD | 50.0% |
| 1997 FY | -9.2 Million USD | -300.0% |
| 1997 Q4 | -7.8 Million USD | -3800.0% |
| 1996 Q4 | -700 Thousand USD | 0.0% |
| 1996 Q3 | -700 Thousand USD | -133.33% |
| 1996 Q2 | -300 Thousand USD | 25.0% |
| 1996 FY | -2.3 Million USD | 4.17% |
| 1996 Q1 | -400 Thousand USD | 84.0% |
| 1995 Q4 | -2.5 Million USD | -2600.0% |
| 1995 Q2 | -900 Thousand USD | -200.0% |
| 1995 FY | -2.4 Million USD | 0.0% |
| 1995 Q3 | 100 Thousand USD | 111.11% |
| 1995 Q1 | -300 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1213.359% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -247.687% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 1.726% |
| Nascent Biotech, Inc. | -2.22 Million USD | -686.545% |
| Rebus Holdings, Inc. | -664 Thousand USD | -2541.416% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 121.428% |
| Qrons Inc. | -643.67 Thousand USD | -2624.814% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -4402.143% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 68.403% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -4121.393% |
| Skye Bioscience, Inc. | -13.67 Million USD | -28.286% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 75.568% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 456.86% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -6601.283% |
| SQZ Biotechnologies Company | -75.82 Million USD | 76.869% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -515.294% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1041.826% |
| Mesoblast Limited | -84.14 Million USD | 79.157% |
| Marizyme, Inc. | -34.08 Million USD | 48.546% |
| Genus plc | 6.4 Million USD | 374.047% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 280.026% |
| Pharming Group N.V. | -4.87 Million USD | -259.439% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -782.919% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1783.12% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -110.048% |
| ContraFect Corporation | -56.88 Million USD | 69.17% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -285.073% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1151.007% |
| IMV Inc. | -38.67 Million USD | 54.646% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -537.587% |
| MultiCell Technologies, Inc. | -722.81 USD | -2426402.124% |
| ONE Bio Corp. | 13.68 Million USD | 228.195% |
| Accustem Sciences Inc. | -3.74 Million USD | -368.154% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 70.268% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -3530.797% |
| Q BioMed Inc. | -3.44 Million USD | -409.024% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 595.452% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -567.511% |
| Biomind Labs Inc. | -1 Million USD | -1637.218% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 68.095% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -504.533% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -163.823% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -840.747% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -58457.025% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -10.519% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -807.529% |
| GB Sciences, Inc. | -1.42 Million USD | -1134.698% |
| Alpha Cognition Inc. | -9.7 Million USD | -80.71% |
| HST Global, Inc. | -140.9 Thousand USD | -12347.217% |
| CSL Limited | 3.7 Billion USD | 100.474% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1459.152% |
| Halberd Corporation | -75.05 Thousand USD | -23269.753% |
| Enzolytics Inc. | -2.14 Million USD | -716.223% |
| Agentix Corp. | -1.37 Million USD | -1178.58% |
| Resverlogix Corp. | -12.74 Million USD | -37.572% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -453.582% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 95.874% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1579.981% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -500.765% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -1010.517% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -415.099% |
| AVAX Technologies, Inc. | 6.69 Million USD | 362.055% |
| Zenith Capital Corp. | -8.94 Million USD | -96.12% |
| Genscript Biotech Corporation | -415.79 Million USD | 95.782% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -100577.343% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -614.327% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -10126.253% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -774.869% |
| Kadimastem Ltd | -3.04 Million USD | -476.893% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1682.323% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -1296.417% |
| BioStem Technologies, Inc. | -7.77 Million USD | -125.467% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -9564.16% |
| LadRx Corporation | -3.82 Million USD | -358.701% |
| Cell Source, Inc. | -4.32 Million USD | -305.494% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2453.17% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2453.17% |
| NovAccess Global Inc. | -2.46 Million USD | -611.014% |
| Affymax, Inc. | -15.04 Million USD | -16.569% |
| Itoco Inc. | -919.14 Thousand USD | -1808.197% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -313.81% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1467.382% |
| Mobile Lads Corp. | -554.55 Thousand USD | -3062.745% |
| CytoDyn Inc. | -18.05 Million USD | 2.874% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -69582.161% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -7869.447% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -3005.77% |
| SYBLEU INC | -149.18 Thousand USD | -11656.938% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -865.634% |
| International Stem Cell Corporation | -663 Thousand USD | -2545.4% |
| Bioxytran, Inc. | -3.82 Million USD | -359.118% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -33218.769% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -86129.105% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 51.638% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -983.993% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -2283.551% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -463.774% |
| Neutra Corp. | -229.48 Thousand USD | -7542.732% |
| PureTech Health plc | -146.19 Million USD | 88.003% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 18.39% |
| IXICO plc | -1.43 Million USD | -1120.529% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -84.796% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 85.601% |
| CSL Limited | 3.81 Billion USD | 100.46% |
| Cellectis S.A. | -108.85 Million USD | 83.888% |